Ethyl 3-methylpyrazolo[1,5-a]pyridine-2-carboxylate, 97%, 5g

((2S,5R)-5-(5-Methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,5-dihydrofuran-2-yl)methyl benzoate, 95.0%, 100mg

(E)-2-(2,6-Dichlorostyryl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 1g

Morpholin, min. 99 %, zur Synthese, 500 ml, Glasverpackung

1H-Benzo[d]imidazol-4-ol, 95.0%, 1g

(S)-2-Amino-2-(2-bromo-4-fluorophenyl)acetic acid hydrochloride, 98%, 5g

1-Chloro-3-(methylsulfonyl)propane, 95.0%, 250mg

N-[2-(ethylthio)ethyl]cyclohexanamine hydrochloride, 95.0%, 5g

6-(Hydroxymethyl)-2-naphthoic acid, 98%, 100mg

tert-Butyl 4-(3-aminophenyl)piperazine-1-carboxylate, 95.0%, 5g

(S)-2-AMINO-4-CYCLOHEXYL BUTANOIC ACID, 97.0%, 250mg

Zubehör CP-Spitzen für Direktverdrängerpipetten Standard, 50 bis 250 µl, Estim. für, M250E, Rack (10 x 96), 960 Stück

3-(4-Fluorophenoxy)azetidine, 95+%, 100mg